We benchmarked RIDDEN on various receptor perturbation datasets, including the recent in vivo Immune Dictionary data https://nature.com/articles/s41586-023-06816-9, and found good predictive performance. 3/n
Comments
Log in with your Bluesky account to leave a comment
Using an IO dataset of nivolumab-treated renal cancer patients, we found that:
- PD1 or PDL1 expression didn't predict survival
- PD1 activity (from RIDDEN) did associate with survival.
This shows that receptor activity could be a more effective biomarker than expression. 5/n
Thanks to all the coauthors, Eszter Varga, Daniel Dimitrov, @juliosaezrod.bsky.social , László Hunyady and especially to first author Szilvia Barsi who led this project from start to finish! 6/6
Comments
- PD1 or PDL1 expression didn't predict survival
- PD1 activity (from RIDDEN) did associate with survival.
This shows that receptor activity could be a more effective biomarker than expression. 5/n